We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App





Thermo Fisher Showcases Diagnostics Innovation Across Therapeutic Areas

By LabMedica International staff writers
Posted on 30 Jul 2024

Thermo Fisher Scientific Inc. More...

(Waltham, MA; USA) is showcasing its broad diagnostics portfolio and hosting a series of customer-led workshops and presentations that highlight industry developments and the company’s latest innovations at ADLM 2024. The company’s conference booth is designed as a “Story Tunnel” to lead visitors along a journey of research and clinical solutions impacting patient care across oncology, infectious disease, women’s health, toxicology, allergy and autoimmune diseases, and transplant and protein diagnostics.

Supporting innovation in protein diagnostics, Thermo Fisher is demonstrating the Optilite Analyzer, along with providing an overview of the Freelite assays, which received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to evaluate monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. The integration of liquid chromatography mass spectrometry (LC-MS) into the healthcare setting also continues, as demonstrated by the recent launch of the Thermo Scientific Stellar mass spectrometer, an LC-MS solution that combines fast throughput and high sensitivity to advance clinical research. The system powers the conversion of scientific discoveries into clinical research applications.

Recognized as one of TIME’s best inventions and the first immunoassays to receive FDA breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, Thermo Fisher’s test is also being featured in the ‘Story Tunnel’ booth where visitors can learn how the novel biomarkers are impacting treatment decisions for a growing number of mothers and their unborn children. Early test adopter Dr. Sarosh Rana, professor of Obstetrics and Gynecology and Section Chief of Maternal-Fetal Medicine at the University of Chicago, is a key opinion leader attending ADLM sharing her insights on the risks of preeclampsia and how Thermo Fisher’s assays are supporting maternal health at her hospital.

Following its exclusive distribution agreement with Aesku Group, Thermo Fisher now offers Aesku’s portfolio of FDA-cleared IFA products, automated instruments, like the Helios HTC and software, in addition to EliA assays, which help provide unparalleled focus on automation and workflow efficiency to support earlier diagnosis and improve care for patients with autoimmune conditions. Thermo Fisher is showcasing these capabilities in a presentation titled, Automated IFA now available through Thermo Fisher in the US. Enabling faster and more accurate diagnoses for patients with complex autoimmune conditions, the Helios IFA System together with the EliA portfolio, run on Phadia Laboratory Systems, meets the evolving needs of laboratories and allows for more efficient workflows by providing the most comprehensive suite of automated diagnostic systems and methodologies available in the U.S. market.

The World Health Organization (WHO) estimates that about 10% of people initiating antiretroviral treatment (ART) globally carry drug-resistant HIV strains. Stephen Williams, PhD, clinical director at Thermo Fisher Scientific, is hosting a workshop titled, Testing for HIV Integrase Inhibitor Resistance: 2024 and Beyond. The discussion features perspectives from key opinion leaders in the HIV-DR field to discuss the current state of drug resistance globally and new challenges related to the detection and monitoring of HIV-DR in the era of integrase strand transfer inhibitors. The antibiotic stewardship (ABS) landscape continues to evolve, which is driving the way ABS committees operate. To help shed light on this evolution, Dr. Michael Broyles, Pharm D, director of medical affairs at Thermo Fisher, is leading an industry workshop to discuss a path forward to help meet changing requirements for ABS and improve clinical outcomes during his presentation titled, Navigating Antibiotic Stewardship Regulations with Procalcitonin.

“As the demands of the healthcare industry evolve, we continuously collaborate with our customers to provide advanced and reliable diagnostics solutions to help accelerate the development of new therapies and disease identification, ultimately supporting more informed treatment decisions for patients,” said Puneet Sarin, senior vice president, and president, specialty diagnostics at Thermo Fisher. “With our product innovation, we’re also strengthening our distribution channels to ensure our leading-edge solutions are accessible to those who need them. We are driven by our Mission to enable our customers to make the world healthier, cleaner, and safer, supporting our customers in the moments that matter most.”

Related Links:
Thermo Fisher Scientific Inc.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
Glucose Tolerance Test
NERL Trutol
New
Uric Acid Meter
PA-16
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.